Results 71 to 80 of about 29,662,057 (278)

ASSESSMENT OF SODIUM-GLUCOSE CO-TRANSPORTER INHIBITOR IN COMBINATION WITH INSULIN ON METABOLIC PARAMETERS AND RENAL MORPHOFUNCTIONAL CHANGES IN RATS WITH EXPERIMENTAL DIABETES MELLITUS

open access: yesJuvenis Scientia, 2017
Sodium-glucose co-transporter type 2 inhibitors belong to modern class of oral hypoglycemic drugs, exerting its effect through the reduction of renal glucose reabsorption.
D. A. Lebedev   +4 more
doaj  

"Histological and Immunohistochemical Study of the Protective Effect of Sodium Glucose Co-transporter 2 (SGLT2) Inhibitors on Streptozotocin Induced Pancreatic Damage In Adult Male Albino Rats" [PDF]

open access: yesMinia Journal of Medical Research
Background: SGLT2 inhibitor is a type of medication prescribed for treatment of type 2 diabetes. By prevention the reabsorption of glucose in the kidneys, these drugs facilitate glucose removal through urine.Aim: Investigate protective effect SGLT2 ...
Abdel Hamid AboBakr   +3 more
doaj   +1 more source

SLC2A9 is a high-capacity urate transporter in humans [PDF]

open access: yes, 2008
Background Serum uric acid levels in humans are influenced by diet, cellular breakdown, and renal elimination, and correlate with blood pressure, metabolic syndrome, diabetes, gout, and cardiovascular disease. Recent genome-wide association scans have
Doblado M   +240 more
core   +1 more source

An Engineered Biomimetic Nanoreactor With Cascade Functions for Targeted and Combinatorial Therapy of Ischemic Stroke

open access: yesAdvanced Healthcare Materials, EarlyView.
Preparation of RVG‐modified erythrocyte membrane‐coated HMPB nanocarriers loaded with L‐arginine and NBP (RM@HPAN) and its neuroprotective mechanism. After intravenous injection, RM@HPAN achieves prolonged circulation, RVG‐29‐mediated BBB penetration, and ischemic accumulation.
Shaofa Li   +9 more
wiley   +1 more source

Sodium–glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy

open access: yes, 2017
Background: The effects of sodium–glucose co-transporter type 2 inhibitors on home blood pressure were examined in type 2 diabetes with nephropathy.
Osamu Tomonaga   +4 more
core   +1 more source

Renal Effects of Sodium-Glucose Co-Transporter Inhibitors [PDF]

open access: yes, 2019
Sodium-glucose co-transporter 2 (SGLT2) inhibitors immediately reduce the glomerular filtration rate (GFR) in patients with type 2 diabetes mellitus. When given chronically, they confer benefit by markedly slowing the rate at which chronic kidney disease
Thomson, Scott C, Vallon, Volker
core   +1 more source

Near‐Infrared Light‐Activated Polydopamine Nanoparticles Conjugated With Transferrin Peptides for Enhanced Brain Accumulation

open access: yesAdvanced Healthcare Materials, EarlyView.
This study demonstrates that Tf‐PDA NPs combine a receptor‐mediated targeting with mild photothermal activation to enhance nanoparticle accumulation in the brain. NIR‐activated Tf‐PDA NPs increase BBB permeability to NPs in vitro and in vivo without inducing cytotoxicity or adverse immune responses.
Rafaela Ferrão   +5 more
wiley   +1 more source

REVIEW ONPHARMACOKINETICS OF EMPAGLIFLOZIN, AN INHIBITOR OF THE SODIUM GLUCOSE CO-TRANSPORTER-2 (SGLT-2) [PDF]

open access: yes, 2017
Empagliflozin is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), which is found almost exclusively in the proximal tubules of nephrotic components in the kidneys.
Nermeen Ashoush
core   +3 more sources

sj-pdf-2-vmj-10.1177_1358863X221101653 – Supplemental material for Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials

open access: yes, 2022
Supplemental material, sj-pdf-2-vmj-10.1177_1358863X221101653 for Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials by Dimitrios Patoulias, Christodoulos ...
Vassilios Vassilikos (4330294)   +6 more
core   +1 more source

Human iPSC‐Derived Tissue‐Engineered Nigrostriatal Pathway for Chronic Restoration of Dopaminergic Axon Tracts in a Rat Parkinson's Model

open access: yesAdvanced Healthcare Materials, EarlyView.
Inspired by conventional cell therapy and emerging bioengineering approaches, the tissue‐engineered nigrostriatal pathway (TE‐NSP) has an anatomically‐inspired design comprising a population of human dopaminergic neurons with unidirectional, long‐projecting axon tracts.
Wisberty J. Gordián‐Vélez   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy